
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/493802/publications.pdf Version: 2024-02-01



MADER RAIDA

#	Article	IF	CITATIONS
1	Multi-Target-Directed Ligands in Alzheimer's Disease Treatment. Current Medicinal Chemistry, 2011, 18, 4949-4975.	1.2	219
2	Structure-Based Search for New Inhibitors of Cholinesterases. International Journal of Molecular Sciences, 2013, 14, 5608-5632.	1.8	200
3	Recent Developments in Cholinesterases Inhibitors for Alzheimers Disease Treatment. Current Medicinal Chemistry, 2007, 14, 2654-2679.	1.2	186
4	Advances in GPCR Modeling Evaluated by the GPCR Dock 2013 Assessment: Meeting New Challenges. Structure, 2014, 22, 1120-1139.	1.6	149
5	Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation. European Journal of Medicinal Chemistry, 2017, 125, 676-695.	2.6	85
6	Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors. European Journal of Medicinal Chemistry, 2013, 62, 311-319.	2.6	61
7	Development of multifunctional, heterodimeric isoindoline-1,3-dione derivatives as cholinesterase and β-amyloid aggregation inhibitors with neuroprotective properties. European Journal of Medicinal Chemistry, 2015, 92, 738-749.	2.6	60
8	Novel biphenyl bis -sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies. Bioorganic Chemistry, 2016, 64, 13-20.	2.0	56
9	Design and synthesis of new barbituric- and thiobarbituric acid derivatives as potent urease inhibitors: Structure activity relationship and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2015, 23, 6049-6058.	1.4	53
10	Synthesis and biological evaluation of novel oxadiazole derivatives: A new class of thymidine phosphorylase inhibitors as potential anti-tumor agents. Bioorganic and Medicinal Chemistry, 2014, 22, 1008-1015.	1.4	51
11	Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase. Bioorganic Chemistry, 2015, 63, 64-71.	2.0	51
12	Organocatalyzed solvent free an efficient novel synthesis of 2,4,5-trisubstituted imidazoles for α-glucosidase inhibition to treat diabetes. Bioorganic Chemistry, 2015, 58, 65-71.	2.0	51
13	Novel synthesis of dihydropyrimidines for α-glucosidase inhibition to treat type 2 diabetes: In vitro biological evaluation and in silico docking. Bioorganic Chemistry, 2014, 54, 96-104.	2.0	49
14	Design, Synthesis and Evaluation of Novel 2â€(Aminoalkyl)â€isoindolineâ€1,3â€dione Derivatives as Dualâ€Bindi Site Acetylcholinesterase Inhibitors. Archiv Der Pharmazie, 2012, 345, 509-516.	ng 2.1	48
15	Design, Synthesis, and Biological Evaluation of 1-Benzylamino-2-hydroxyalkyl Derivatives as New Potential Disease-Modifying Multifunctional Anti-Alzheimer's Agents. ACS Chemical Neuroscience, 2018, 9, 1074-1094.	1.7	47
16	Isoindoline-1,3-dione derivatives targeting cholinesterases: Design, synthesis and biological evaluation of potential anti-Alzheimer's agents. Bioorganic and Medicinal Chemistry, 2015, 23, 1629-1637.	1.4	44
17	Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. Bioorganic and Medicinal Chemistry, 2015, 23, 2445-2457.	1.4	42
18	EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 1341-1354.	1.9	41

#	Article	IF	CITATIONS
19	Identification of 1,2,4-triazoles as new thymidine phosphorylase inhibitors: Future anti-tumor drugs. Bioorganic Chemistry, 2019, 85, 209-220.	2.0	41
20	Dual Inhibitors of Amyloid-β and Tau Aggregation with Amyloid-β Disaggregating Properties: Extended <i>In Cellulo</i> , <i>In Silico</i> , and Kinetic Studies of Multifunctional Anti-Alzheimer's Agents. ACS Chemical Neuroscience, 2021, 12, 2057-2068.	1.7	36
21	Investigation of lipophilicity of anticancer-active thioquinoline derivatives. Biomedical Chromatography, 2007, 21, 123-131.	0.8	32
22	Antiarrhythmic properties of phenylpiperazine derivatives of phenytoin with α1-adrenoceptor affinities. Bioorganic and Medicinal Chemistry, 2012, 20, 2290-2303.	1.4	29
23	Synthesis, Molecular Modelling and Biological Evaluation of Novel Heterodimeric, Multiple Ligands Targeting Cholinesterases and Amyloid Beta. Molecules, 2016, 21, 410.	1.7	29
24	Design, Synthesis, and Biological Evaluation of 2-(Benzylamino-2-Hydroxyalkyl)Isoindoline-1,3-Diones Derivatives as Potential Disease-Modifying Multifunctional Anti-Alzheimer Agents. Molecules, 2018, 23, 347.	1.7	27
25	Search for new multi-target compounds against Alzheimer's disease among histamine H3 receptor ligands. European Journal of Medicinal Chemistry, 2020, 185, 111785.	2.6	27
26	Î ³ -Aminobutyric acid transporters as relevant biological target: Their function, structure, inhibitors and role in the therapy of different diseases. International Journal of Biological Macromolecules, 2020, 158, 750-772.	3.6	27
27	Synthesis, biological evaluation and molecular modeling of new tetrahydroacridine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2015, 23, 5610-5618.	1.4	26
28	Dualâ€Acting Diether Derivatives of Piperidine and Homopiperidine with Histamine H ₃ Receptor Antagonistic and Anticholinesterase Activity. Archiv Der Pharmazie, 2012, 345, 591-597.	2.1	25
29	2,3-Dihydro-1H-cyclopenta[b]quinoline Derivatives as Acetylcholinesterase Inhibitors—Synthesis, Radiolabeling and Biodistribution. International Journal of Molecular Sciences, 2012, 13, 10067-10090.	1.8	24
30	Design and Synthesis of New Dual Binding Site Cholinesterase Inhibitors: in vitro Inhibition Studies with in silico Docking. Letters in Drug Design and Discovery, 2014, 11, 331-338.	0.4	23
31	Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors. European Journal of Medicinal Chemistry, 2010, 45, 5602-5611.	2.6	21
32	Synthesis, thymidine phosphorylase inhibition and molecular modeling studies of 1,3,4-oxadiazole-2-thione derivatives. Bioorganic Chemistry, 2015, 60, 37-41.	2.0	21
33	Tetrahydroacridine derivatives with dichloronicotinic acid moiety as attractive, multipotent agents for Alzheimer's disease treatment. European Journal of Medicinal Chemistry, 2018, 145, 760-769.	2.6	21
34	Cholinesterase inhibitory activity of chlorophenoxy derivatives—Histamine H3 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4140-4145.	1.0	20
35	Discovery of butyrylcholinesterase inhibitors among derivatives of azaphenothiazines. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 98-106.	2.5	19
36	Biological evaluation and molecular docking of novel 1,3,4-thiadiazole-resorcinol conjugates as multifunctional cholinesterases inhibitors. Bioorganic Chemistry, 2021, 107, 104617.	2.0	19

#	Article	IF	CITATIONS
37	Novel carbamate derivatives as selective butyrylcholinesterase inhibitors. Bioorganic Chemistry, 2018, 78, 29-38.	2.0	18
38	Application of Computational Methods for the Design of BACE-1 Inhibitors: Validation of in Silico Modelling. International Journal of Molecular Sciences, 2014, 15, 5128-5139.	1.8	17
39	Tetrahydroacridine derivatives with fluorobenzoic acid moiety as multifunctional agents for Alzheimer's disease treatment. Bioorganic Chemistry, 2017, 72, 315-322.	2.0	17
40	New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 158-170.	2.5	17
41	Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 207, 112743.	2.6	17
42	Computational approach for the assessment of inhibitory potency against beta-amyloid aggregation. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 212-216.	1.0	16
43	A Hybrid Approach to Structure and Function Modeling of G Protein-Coupled Receptors. Journal of Chemical Information and Modeling, 2016, 56, 630-641.	2.5	14
44	Hybrid approach to structure modeling of the histamine H3 receptor: Multi-level assessment as a tool for model verification. PLoS ONE, 2017, 12, e0186108.	1.1	14
45	4-tert-Pentylphenoxyalkyl derivatives – Histamine H3 receptor ligands and monoamine oxidase B inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3596-3600.	1.0	13
46	Search for multifunctional agents against Alzheimer's disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives. Bioorganic Chemistry, 2019, 90, 103084.	2.0	13
47	Novel application of capillary electrophoresis with a liposome coated capillary for prediction of blood-brain barrier permeability. Talanta, 2020, 217, 121023.	2.9	13
48	Search for anticonvulsant and analgesic active derivatives of dihydrofuran-2(3H)-one. Bioorganic and Medicinal Chemistry, 2012, 20, 6533-6544.	1.4	12
49	New Tacrine Analogs as Acetylcholinesterase Inhibitors — Theoretical Study with Chemometric Analysis. Molecules, 2013, 18, 2878-2894.	1.7	12
50	Discovery of New Cyclopentaquinoline Analogues as Multifunctional Agents for the Treatment of Alzheimer's Disease. International Journal of Molecular Sciences, 2019, 20, 498.	1.8	12
51	Biological Evaluation, Molecular Docking, and SAR Studies of Novel 2-(2,4-Dihydroxyphenyl)-1H- Benzimidazole Analogues. Biomolecules, 2019, 9, 870.	1.8	12
52	Structure Modeling of the Norepinephrine Transporter. Biomolecules, 2020, 10, 102.	1.8	12
53	Multiple Ligands Targeting Cholinesterases and βâ€Amyloid: Synthesis, Biological Evaluation of Heterodimeric Compounds with Benzylamine Pharmacophore. Archiv Der Pharmazie, 2015, 348, 556-563.	2.1	11
54	Determination of lipophilicity of <i>α</i> â€(4â€phenylpiperazine) derivatives of <i> N</i> â€benzylamides using chromatographic and computational methods. Biomedical Chromatography, 2008, 22, 428-432.	0.8	10

#	Article	IF	CITATIONS
55	Synthesis and Biological Activity of New 2,3-dihydro-1H-cyclopenta[b]- quinoline Derivatives as Acetylcholinesterase Inhibitors. Letters in Drug Design and Discovery, 2012, 9, 645-654.	0.4	10
56	Structure modeling of γ-aminobutyric acid transporters – Molecular basics of ligand selectivity. International Journal of Biological Macromolecules, 2020, 158, 1380-1389.	3.6	10
57	Organocatalyzed Novel Synthetic Methodology for Highly Functionalized Piperidines as Potent αâ€Glucosidase Inhibitors. Archiv Der Pharmazie, 2016, 349, 724-732.	2.1	9
58	Lipophilic properties of antiâ€Alzheimer's agents determined by micellar electrokinetic chromatography and reversedâ€phase thinâ€layer chromatography. Electrophoresis, 2017, 38, 1268-1275.	1.3	9
59	Synthesis, physicochemical and biological studies of technetium-99m labeled tacrine derivative as a diagnostic tool for evaluation of cholinesterase level. Bioorganic and Medicinal Chemistry, 2017, 25, 912-920.	1.4	9
60	Multidirectional <i>inÂvitro</i> and <i>in cellulo</i> studies as a tool for identification of multi-target-directed ligands aiming at symptoms and causes of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1944-1952.	2.5	9
61	Characteristics of metabolic stability and the cell permeability of 2â€pyrimidinylâ€piperazinylâ€alkyl derivatives of 1Hâ€imidazo[2,1 â€f]purineâ€2,4(3 H ,8 H)â€dione with antidepressant―and anxiolyticâ€like activities. Chemical Biology and Drug Design, 2019, 93, 511-521.	1.5	8
62	Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease. Bioorganic Chemistry, 2021, 114, 105129.	2.0	8
63	Electrophoretically mediated microanalysis technique as a tool for the rapid screening of novel acetylcholinesterase inhibitors. Acta Poloniae Pharmaceutica, 2009, 66, 357-62.	0.3	8
64	Synthesis, Biological Activity and Molecular Modeling of 4-Fluoro-N-[ï‰-(1,2,3,4-tetrahydroacridin-9-ylamino)-alkyl]-benzamide Derivatives as Cholinesterase Inhibitors. Arzneimittelforschung, 2012, 62, 655-660.	0.5	7
65	Study of early stages of amyloid AÎ ² 13-23 formation using molecular dynamics simulation in implicit environments. Computational Biology and Chemistry, 2015, 56, 13-18.	1.1	7
66	Synthesis, physicochemical and biological evaluation of tacrine derivative labeled with technetium-99m and gallium-68 as a prospective diagnostic tool for early diagnosis of Alzheimer's disease. Bioorganic Chemistry, 2019, 91, 103136.	2.0	7
67	New hybrids of tacrine and indomethacin as multifunctional acetylcholinesterase inhibitors. Chemical Papers, 2021, 75, 249-264.	1.0	7
68	Guanidine Derivatives: How Simple Structural Modification of Histamine H ₃ R Antagonists Has Led to the Discovery of Potent Muscarinic M ₂ R/M ₄ R Antagonists. ACS Chemical Neuroscience, 2021, 12, 2503-2519.	1.7	7
69	Determination of lipophilicity of γâ€butyrolactone derivatives with anticonvulsant and analgesic activity using micellar electrokinetic chromatography. Electrophoresis, 2013, 34, 3079-3085.	1.3	6
70	New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 3765.	1.8	6
71	Novel Functionalized Amino Acids as Inhibitors of GABA Transporters with Analgesic Activity. ACS Chemical Neuroscience, 2021, 12, 3073-3100.	1.7	6
72	Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity. European Journal of Medicinal Chemistry, 2021, 221, 113512.	2.6	6

#	Article	IF	CITATIONS
73	Molecular Modeling Studies on the Multistep Reactivation Process of Organophosphate-Inhibited Acetylcholinesterase and Butyrylcholinesterase. Biomolecules, 2021, 11, 169.	1.8	6
74	Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 437-449.	2.5	4
75	Application of a Library of Artificial Receptors Formed by Selfâ€Organization of <i>N</i> â€Lipidated Peptides Immobilized on Cellulose for Preliminary Studies of Binding of <i>N</i> â€Phenylpiperazines. QSAR and Combinatorial Science, 2009, 28, 728-736.	1.5	3
76	Novel pyridineâ€2,4,6â€ŧricarbohydrazide thiourea compounds as small key organic molecules for the potential treatment of typeâ€2 diabetes mellitus: <i>In vitro</i> studies against yeast α―and βâ€glucosidase and <i>in silico</i> molecular modeling. Archiv Der Pharmazie, 2018, 351, 1700236.	2.1	3
77	Determination of ligand efficiency indices in a group of 7Hâ€purineâ€2,6â€dione derivatives with psychotropic activity using micellar electrokinetic chromatography. Electrophoresis, 2018, 39, 2446-2453.	1.3	3
78	Biphenylalkoxyamine Derivatives–Histamine H3 Receptor Ligands with Butyrylcholinesterase Inhibitory Activity. Molecules, 2021, 26, 3580.	1.7	3
79	Chromatographic and computational studies of the physicochemical properties of cholinesterase inhibitors — alkyl- and arylcarbamate derivatives of <i>N</i> -benzylpiperidine and <i>N</i> -benzylpiperazine. Journal of Planar Chromatography - Modern TLC, 2010, 23, 359-364.	0.6	2
80	The Lipophilicity Estimation of Selected Dermatological Drugs Using Micellar Electrokinetic Chromatography Method. Journal of Liquid Chromatography and Related Technologies, 2015, 38, 1435-1438.	0.5	2
81	Design, Synthesis, and In Vitro Antiproliferative Activity of Hydantoin and Purine Derivatives with the 4-Acetylphenylpiperazinylalkyl Moiety. Materials, 2021, 14, 4156.	1.3	1
82	Multilevel virtual screening approach for discovery of thymidine phosphorylase inhibitors as potential anticancer agents. Journal of Molecular Structure, 2022, 1249, 131648.	1.8	0
83	Abstract 4716: Therapeutic utility of EC359 for targeting oncogenic LIFR signaling in triple negative breast cancer. , 2019, , .		0